AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Dopamine Receptor Agonists

Summary

Researchers at Purdue University have developed a class of novel D1 dopamine agonists, or stimulants, which may be useful in treating the symptoms of Parkinson's disease and other working memory and cognitive deficits. This series of compounds has potent and selective activity at dopamine D1 receptors, making them useful therapeutic agents in hypodopaminergic conditions. Recent studies have also shown that dopamine D1 agonists are able to reverse drug-induced and age-related deficits in working memory.

Technology Benefits

Novel class of dopamine agonists Potent and selective activity Clinical precedent

Technology Application

Pharmaceutical companies

Detailed Technology Description

David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology

Countries

Europe

Application No.

EP2421862

Country/Region

USA

For more information, please click Here